Correlation between Serum 25-Hydroxyvitamin D Level and Hematological Profile in Cystic Fibrosis Patients
Keywords:
Cystic Fibrosis, Hematological Profile, Serum 25-Hydroxyvitamin D, Vitamin D DeficiencyAbstract
Background: A genetic disease called cystic fibrosis (CF) is caused by mutations in the CFTR gene. This disorder may cause systemic consequences such as vitamin D insufficiency and modifications in hematological functions. Objective: To investigate the relationship between a person's hematological profile as well as serum 25-hydroxyvitamin D (25-HVD) levels in cystic fibrosis patients was the goal of this research. Methodology: A cross-sectional investigation was carried out at Ayub Medical Complex, Abbottabad, involving 310 CF patients aged 18 years and older. Descriptive statistics, Pearson correlation coefficient, linear regression, and subgroup analyses were used in the collection and analysis of data on demographic traits, hematological parameters, and serum 25-HVD levels. Results: There were differences in the serum vitamin D levels: 90 people (29%) had less than 20 ng/mL, 140 people (45.2%) had between 20 and 29 ng/mL, and 80 people (25.6%) had more than 30 ng/mL. There were negative relationships with mean corpuscular hemoglobin concentration (-0.15), white blood cell (WBC) count (-0.12), and hematocrit (-0.18), but positive connections with vitamin D levels (r = 0.32). Hemoglobin (p = 0.042) and vitamin D levels (p = 0.012) showed gender differences, with men having greater values. Conclusion: This research emphasizes the correlation between blood vitamin D levels and hematological markers in people with CF. There were differences among the sexes and a trend showing a decline in vitamin D levels as the condition became worse. For cystic fibrosis patients to get successful disease care, thorough monitoring of both parameters is necessary.References
Ehre C, Ridley C, Thornton DJ. Cystic fibrosis: an inherited disease affecting mucin-producing organs. Int J Biochem Cell Biol. 2014;52:136-45.
Kreda SM, Davis CW, Rose MC. CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med. 2012;2(9):a009589.
Pincikova T, Paquin-Proulx D, Sandberg JK, Flodström-Tullberg M, Hjelte L. Vitamin D treatment modulates immune activation in cystic fibrosis. Clin Exp Immunol. 2017;189(3):359-71.
Giannini S, Giusti A, Minisola S, Napoli N, Passeri G, Rossini M, et al. The immunologic profile of vitamin D and its role in different immune-mediated diseases: an expert opinion. Nutrients. 2020;14(3):473.
El Hamdouni M, Ahid S, Bourkadi JE, Benamor J, Hassar M, Cherrah Y. Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco. Infection. 2020;48:43-50.
Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. American Family Physician. 2003; 68(10):2001-09.
Daley T, Hughan K, Rayas M, Kelly A, Tangpricha V. Vitamin D deficiency and its treatment in cystic fibrosis. J Cyst Fibros. 2019;18:S66-73.
Chesdachai S, Tangpricha V. Treatment of vitamin D deficiency in cystic fibrosis. J Steroid Biochem Mol Biol. 2016;164:36-9.
Medrano M, Carrillo-Cruz E, Montero I, Perez-Simon JA. Vitamin D: effect on haematopoiesis and immune system and clinical applications. Int J Mol Sci. 2018;19(9):2663.
Umar M, Sastry KS, Chouchane AI. Role of vitamin D beyond the skeletal function: a review of the molecular and clinical studies. Int J Mol Sci. 2018;19(6):1618.
Rebelos E, Tentolouris N, Jude E. The role of vitamin D in health and disease: a narrative review on the mechanisms linking vitamin d with disease and the effects of supplementation. Drugs. 2020;83(8):665-85.
Moustaki M, Loukou I, Priftis KN, Douros K. Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis. World J Clin Pediatr. 2017;6(3):132.
Rocha RM, Bittencourt MI, Rangel FO, Rey HC, Ferreira FA, Almeida Jr GL, et al. Is anemia a predictor of inhospital complications and mortality in decompensated heart failure?. Crit Care. 2005;9(Suppl 2):P25.
Biciuşcă V, Petrescu IO, Singer CE, Oancea AG, Petrescu AM, Stan IS, et al. Multidisciplinary approach to patients with manifestations and pulmonary complications of cystic fibrosis. Rom J Morphol Embryol. 2020;61(2):397.
Wani WA, Nazir M, Bhat JI, Ahmad QI, Charoo BA, Ali SW. Vitamin D status correlates with the markers of cystic fibrosis-related pulmonary disease. Pediatr Neonatol. 2019;60(2):210-5.
Von Drygalski A, Biller J. Anemia in cystic fibrosis: incidence, mechanisms, and association with pulmonary function and vitamin deficiency. Nutr Clin Pract. 2008;23(5):557-63.
Escobedo-Monge MF, Marcos-Temprano M, Parodi-Román J, Escobedo-Monge MA, Alonso-Vicente C, Torres-Hinojal MC, et al. Calcium, Phosphorus, and Vitamin D Levels in a Series of Cystic Fibrosis Patients: A Cross-Sectional Study. Int J Mol Sci. 2019;25(3):1900.
Tabatabaii SA, Mansouri SS, Azangou-Khyavy M, Zarfeshani H, Khanbabaee G, Gorji FA, et al. The Association of Serum Elements’ Levels with the Severity of Pulmonary Involvement in Cystic Fibrosis Patients. J Compr Pediatr. 2019;14(1).
Böning D, Littschwager A, Hütler M, Beneke R, Staab D. Hemoglobin oxygen affinity in patients with cystic fibrosis. PLoS One. 2014 ;9(6):e97932.
Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferonâ€based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010;51(4):1158-67.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
